| Title | Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors |
| Authors | Yap, Desmond Y. H. McMahon, Lawrence P. Hao, Chuan-Ming Hu, Nan Okada, Hirokazu Suzuki, Yusuke Kim, Sung Gyun Lim, Soo Kun Vareesangthip, Kriengsak Hung, Chi-Chih Nangaku, Masaomi |
| Affiliation | Univ Hong Kong, Queen Mary Hosp, Dept Med, Div Nephrol,Pok Fu Lam, Hong Kong, Peoples R China Monash Univ, Eastern Hlth Clin Sch, Dept Renal & Obstetr Med, Melbourne, Vic, Australia Fudan Univ, Huashan Hosp, Divison Nephrol, Shanghai, Peoples R China Peking Univ, Peking Univ First Hosp, Inst Nephrol, Renal Div,Dept Med, Beijing, Peoples R China Saitama Med Univ, Dept Nephrol, Saitama, Japan Juntendo Univ, Dept Nephrol, Fac Med, Tokyo, Japan Hallym Univ, Dept Internal Med, Sacred Heart Hosp, Seoul, South Korea Univ Malaya, Dept Med, Div Nephrol, Med Ctr, Kuala Lumpur, Malaysia Mahidol Univ, Fac Med, Dept Med, Div Nephrol,Siriraj Hosp, Bangkok, Thailand Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan Univ Tokyo, Div Nephrol & Endocrinol, Grad Sch Med, Tokyo, Japan |
| Keywords | HYPOXIA-INDUCIBLE-FACTOR CHRONIC KIDNEY-DISEASE FACTOR-PROLYL HYDROXYLASE ERYTHROPOIESIS-STIMULATING AGENTS ROXADUSTAT FG-4592 PULMONARY-HYPERTENSION CARDIAC DYSFUNCTION REGULATES HEPCIDIN FACTOR STABILIZERS DARBEPOETIN ALPHA |
| Issue Date | Dec-2020 |
| Publisher | NEPHROLOGY |
| Abstract | Renal anaemia is a common and important complication in patients with chronic kidney disease (CKD). The current standard-of-care treatment for renal anaemia in CKD patients involves ensuring adequate iron stores and administration of erythropoietin stimulating agents (ESA). Hypoxia inducible factor (HIF) is a key transcription factor primarily involved in the cellular regulation and efficiency of oxygen delivery. Manipulation of the HIF pathway by the use of HIF-prolyl hydroxylase inhibitors (HIF-PHI) has emerged as a novel approach for renal anaemia management. Despite it being approved for clinical use in various Asia-Pacific countries, its novelty mandates the need for nephrologists and clinicians generally in the region to well understand potential benefits and harms when prescribing this class of drug. The Asian Pacific society of nephrology HIF-PHI Recommendation Committee, formed by a panel of 11 nephrologists from the Asia-Pacific region who have clinical experience or have been investigators in HIF-PHI studies, reviewed and deliberated on the clinical and preclinical data concerning HIF-PHI. This recommendation summarizes the consensus views of the committee regarding the use of HIF-PHI, taking into account both available data and expert opinion in areas where evidence remains scarce. |
| URI | http://hdl.handle.net/20.500.11897/608174 |
| ISSN | 1320-5358 |
| DOI | 10.1111/nep.13835 |
| Indexed | SCI(E) |
| Appears in Collections: | 第一医院 |
